As a demonstration, tumor-infiltrating lymphocytes (TILs) are frequently present in TN and HER2+ tumor samples and are associated with good prognosis and are predictive of immunotherapy efficacy [7,8,9]. The gene discussed is ERBB2; the disease is neoplasm.